



Glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026; Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099. Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986 Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com CIN: L24299MH1977PLC019982

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Table with columns: Sr. No., Particulars, Standalone (Quarter ended, Nine months ended), Consolidated (Quarter ended, Nine months ended). Rows include Revenue from operations, Expenses, Profit/(loss) before tax, and Earnings per share.

Notes: 1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2 The above results were reviewed by the Audit Committee at its meeting held on 13th February, 2025 and approved by the Board of Directors at its meetings held on 14th February, 2025. 3 The Chief Operating Decision Maker ('CODM') reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals. 4 As at 31st December, 2024, pursuant to Employee Stock Options Scheme 2016, 37,779 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. 5 Exceptional items: Standalone: 31.03.2024 Exceptional item in the standalone result for the year ended 31 March 2024 is Rs 50,703.31 million (gain), primarily comprises of stake sale (net of expenses) in Glenmark Lifescience Limited, remediation, legal, inventory provision and others. Consolidated: 31.03.2024 Exceptional item in the Consolidated result for the year ended 31 March 2024 is Rs 9,009.55 million (loss) primarily comprises of stake sale (net of expenses) in Glenmark Lifescience Limited, impairment of certain block at Monroe facility, De-prioritisation of certain intangibles, settlement & legal cost, remediation cost and working capital adjustments. 6 On July 11 and 12, 2024, the Company sold its entire holding of 96,09,571 Equity Shares representing 7.84% of the total issued and paid-up equity share capital of the Glenmark Life Sciences Limited through the offer dated July 10, 2024 for sale through the stock exchange mechanism. 7 During the quarter, the Company has invested Rs. 1.7 million, equivalent to 34% in equity instruments and Rs. 15.80 million in the Compulsory Convertible Debenture of the O2 Renewable Energy XXIV Private Limited. It is a special purpose vehicle in partnership with O2 Energy SG Pte Ltd. for Generation and transmission of solar energy and other sources of renewable energy. As per the Shareholders Agreement, the Company does not have power to participate in the financial and operating policy decisions of the Company and hence does not exercise significant influence. 8 The list of subsidiaries as of 31st December, 2024 is provided in Annexure A. 9 Diluted EPS has been computed considering the effect of conversion of ESOPs. 10 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited Annexure A List of entities included in the consolidated financial results for the quarter and nine months ended 31 December 2024 1. Glenmark Pharmaceuticals Europe Ltd., U.K. 2. Glenmark Pharmaceuticals S.R.O. 3. Glenmark Pharmaceuticals SK, S.R.O. 4. IGI Therapeutics SA (Formerly known as Ichnos Sciences SA) 5. Glenmark Holding S.A. 6. Glenmark Pharmaceuticals SP z.o.o. 7. Glenmark Pharmaceuticals Inc. 8. Glenmark Therapeutics Inc. 9. Glenmark Farmaceutica Ltda 10. Glenmark Generics S.A. 11. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 12. Glenmark Pharmaceuticals Peru SAC 13. Glenmark Pharmaceuticals Colombia SAS, Colombia 14. Glenmark Uruguay S.A. 15. Glenmark Pharmaceuticals Venezuela, C.A. 16. Glenmark Dominicana SRL 17. Glenmark Pharmaceuticals Egypt S.A.E. 18. Glenmark Pharmaceuticals FZE 19. Glenmark Impex L.L.C. 20. Glenmark Philippines Inc. 21. Glenmark Pharmaceuticals (Nigeria) Ltd 22. Glenmark Pharmaceuticals (Malaysia) Sdn Bhd 23. Glenmark Pharmaceuticals (Australia) Pty Ltd 24. Glenmark South Africa (pty) Ltd 25. Glenmark Pharmaceuticals (Thailand) Co. Ltd 26. Glenmark Pharmaceuticals (Thailand) Co. Ltd 27. Glenmark Pharmaceuticals B.V. 28. Glenmark Arzneimittel GmbH - Germany 29. Glenmark Pharmaceuticals Canada Inc. 30. Glenmark Pharmaceuticals Kenya Ltd 31. Viso Farmaceutica S.L., Spain 32. Glenmark Speciality SA 33. Glenmark Pharmaceuticals Distribution s.r.o. 34. Glenmark Pharmaceuticals Nordic AB 35. Glenmark Ukraine LLC 36. Glenmark-Pharmaceuticals Ecuador S.A. 37. Glenmark Pharmaceuticals Singapore Pte. Ltd. 38. IGI Biotherapeutics SA (Formerly known as Ichnos Sciences Biotherapeutics SA) 39. Ichnos Glenmark Innovation Inc. (Formerly known as Ichnos Sciences Inc.) 40. Glenmark Life Sciences Limited (Upto 6th March 2024) 41. Glenmark Healthcare Limited (with effect from 12th May 2023) 42. Glenmark Farmaceutica SpA (with effect from 1st March 2023) 43. Sintesy Pharma S.R.L (with effect from 10th February 2023) 44. Glenmark Arzenmittel GmbH - Austria (with effect from 9th November 2023)



For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

Mumbai, 14 February 2025

Advertisement for Financial Express newspaper. Text: 'THE BUSINESS DAILY. FOR DAILY BUSINESS.' Logo: 'FINANCIAL EXPRESS'. Website: 'financialexpress.com'. Tagline: 'READ TO LEAD'.

